Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.76 |
| ▸ | TACR2 | P21452 | 1/20 | 0.76 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.76 |
| ▸ | HTR2A | P28223 | 1/20 | 0.76 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1153077 | 1.00 | ADRA2C (0.76) | ADRA2CTACR2ADRA1DHTR2APTH1R | |
| SCHEMBL1152722 | 0.82 | HTR2A (0.52) | ADRA2CTACR2ADRA1DHTR2APTH1R | |
| SCHEMBL1152721 | 0.82 | HTR2A (0.52) | ADRA2CTACR2ADRA1DHTR2APTH1R | |
| SCHEMBL1153957 | 0.81 | ADRA2C (0.52) | ADRA2CTACR2ADRA1DHTR2APTH1R | |
| SCHEMBL1153955 | 0.81 | ADRA2C (0.52) | ADRA2CTACR2ADRA1DHTR2APTH1R | |
| SCHEMBL1152408 | 0.80 | HTR2A (0.51) | ADRA2CTACR2ADRA1DHTR2APTH1R | |
| SCHEMBL1152406 | 0.80 | HTR2A (0.51) | ADRA2CTACR2ADRA1DHTR2APTH1R | |
| SCHEMBL1152275 | 0.72 | CYP46A1 (0.50) | ADRA2CTACR2ADRA1DHTR2APTH1R | |
| SCHEMBL3496644 | 0.71 | ADRA2C (0.53) | ADRA2CTACR2ADRA1DHTR2APTH1R | |
| SCHEMBL7237516 | 0.71 | ADRA2C (0.53) | ADRA2CTACR2ADRA1DHTR2APTH1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| US-6489320-B1 | NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND BENZOXAPINONE FOR TREATMENT OF HIV INFECTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-03 | — | — | US | disclosed |
| US-6140320-A | FOR TREATING HIV(HUMAN IMMUNODEFICIENCY VIRUS) INFECTIONS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | ADRA2C 2095/4885TACR2 4722/4885ADRA1D 3491/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | ADRA2C 2095/4885TACR2 4722/4885ADRA1D 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.